Carvedilol downregulates the VEGF production in human leukemic U937 cell line

Fatemeh Hajighasemi | Amirhossein Gaeini

---

URL :   http://research.shahed.ac.ir/WSR/WebPages/Report/PaperView.aspx?PaperID=116966
Date :  2019/02/26
Publish in :    1sth national congress on inflammation

Link :  http://www.nci.iaari.ir
Keywords : Carvedilol; U937; VEGF

Abstract :

---

Background: Vascular endothelial growth factor (VEGF) has a main role in inflammation and angiogenesis. Also increased VEGF levels in airway inflammation and asthma exacerbation has been revealed. Carvedilol is a nonspecific β blocker has been used for the treatment of hypertension, stroke and congestive heart failure. Moreover the anti-inflammatory and anti-angiogenic properties of carvedilol have been shown. In this study the effect of carvedilol on VEGF production by human leukemic U937 cells have been studied in vitro. Materials and methods: Human leukemic U937 cells were cultured in RPMI 1640 complete medium. Next the cells at logarithmic growth phase were treated with different concentrations of carvedilol (1-100 μg/ml) for 24 hours. The level of VEGF in cell culture supernatants was measured by an enzyme-linked immunosorbent assay (ELISA) kit (R&D system). Results: Carvedilol significantly decreased VEGF production by leukemic U937 cells dose dependently in comparison with untreated control cells. Conclusion: Our results indicated that carvedilol down- regulates the production of VEGF in human leukemic U937 cells. As VEGF has an important role in inflammation, the anti-inflammatory properties of carvedilol may be somewhat due to its inhibitory effects on VEGF production. So it seems that carvedilol might be useful for treatment of inflammatory diseases such as asthma in which VEGF is over-expressed.

http://www.nci.iaari.ir